Of note, the latter TFT gene set appears to have been misattributed to IGLV5-37 (an immunoglobulin with no known TF activity) in the GTRD database, and according to the source publication actually represents targets of the fusion oncoprotein SS18-SSX, which alters the normal regulatory activity of the SWI/SNF (BAF) ATP-dependent chromatin remodeling complex to drive oncogenesis in synovial sarcoma through induction of SOX2 [76]. This evidence concerns the gene SOX2 and synovial sarcoma.